Company news: Amylin vs. Lilly; CVS Caremark

Share this article:
Amylin was granted a temporary restraining order against Eli Lilly & Co. preventing Lilly from going forward with plans to have the same reps detail both Byetta, which it co-promotes with Amylin, and Boehringer Ingelheim's rival type 2 diabetes drug Tradjenta in the US.

The authors of a study of medication adherence that included researchers from Harvard, Brigham and Women's Hospital and CVS Caremark issued their conclusions, calling for: the development of tools allowing prediction and targeting of patients at-risk for non-adherence and prescription abandonment; adoption of a “pharmacy home” concept to simplify care for patients with complex therapies; individualized counseling by pharmacists and healthcare providers; research on the use of financial and other incentives to encourage adherence; a “personalized medicine” approach for pharmacies through pharmacogenomics or individualized counseling with pharmacists; and the use of social networks to improve adherence through family and friends.  
Share this article:

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.